KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int Suppl. 2012;2: 337 414. 142. ESCAPE Trial Group, Wuhl E, Trivelli A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361:1639 1650. 143. Pahor M, Shorr RI, Somes GW, et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Arch Intern Med. 1998;158:1340 1345. 144. Ku E, Gassman J, Appel LJ, et al. BP Control and long-term risk of ESRD and mortality. J Am Soc Nephrol. 2017;28:671 677. 145. Ku E, Glidden DV, Johansen KL, et al. Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease. Kidney Int. 2015;87:1055 1060. 146. Chan JC, So WY, Yeung CY, et al. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. Diabetes Care. 2009;32:977 982. 147. Estacio RO, Coll JR, Tran ZV, et al. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens. 2006;19:1241 1248. 148. Lewis JB, Berl T, Bain RP, et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis. 1999;34:809 817. 149. Juraschek SP, Taylor AA, Wright JT Jr, et al. Orthostatic Hypotension, cardiovascular outcomes, and adverse events: results from SPRINT. Hypertension. 2020;75:660 667. 150. Rocco MV, Sink KM, Lovato LC, et al. Effects of intensive blood pressure treatment on acute kidney injury events in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis. 2018;71:352 361. 151. 